Latest Articles

Publication Date
Steroidal alkaloids as multi-target therapeutics for the treatment of endometriosis.

Endometriosis is a chronic inflammatory disease characterised by ectopic endometrial tissue, progressive fibrosis and chronic pain, with a pathogenesis that goes beyond oestrogen dependence. The central question this review seeks …

Published: July 4, 2026, midnight
Tokishakuyakusan suppresses endometriosis and may be associated with improved fertility during attempts to conceive: A mouse model study.

Tokishakuyakusan (TSS), a traditional Japanese Kampo medicine, is known for its anti-inflammatory and anti-angiogenic properties. This study examined the effects of TSS on fecundity and endometriosis-like lesions during pregnancy in …

Published: June 30, 2026, midnight
The opioid system in endometriosis: implications for endometrial receptivity and reproductive outcomes.

Endometriosis, a chronic inflammatory disease affecting 10-15% of women of reproductive age, remains a leading cause of female subfertility. While current management strategies focus on surgical excision and hormonal suppression, …

Published: June 29, 2026, midnight
Ovarian cancer tumor immune profiles associated with intrauterine device and oral contraceptive use.

Non-hormonal intrauterine devices (IUDs) create an inflammatory uterine environment while oral contraceptives (OC) suppress ovulation and have different associations with ovarian cancer risk. We have evaluated the associations of these …

Published: June 27, 2026, midnight
The hypoxia-epigenetics-ncRNA axis in endometriosis: from molecular cascades to self-sustaining pathogenic circuits.

Endometriosis is a debilitating chronic inflammatory disorder driven by extensive molecular reprogramming. Despite significant bench research into its pathogenesis, translating these molecular discoveries into clinical practices that improve patient outcomes …

Published: June 26, 2026, midnight
Glycolytic reprogramming in endometriosis: molecular mechanisms, immune modulation, and non-hormonal therapeutic opportunities.

Endometriosis is a chronic gynecological disorder characterized by ectopic tissue growth and significant morbidity, yet current hormonal and surgical treatments often fail to prevent recurrence or entail severe side effects. …

Published: May 25, 2026, midnight
Lesion-centric reprogramming: hydrogel-enabled photothermal reset of endometriosis pain.

Endometriosis-associated pelvic pain represents a prototypical failure of systemic therapy for a locally organized, neuroinflammatory disease. Persistent pain arises from the convergence of estrogen-driven lesion survival, chronic inflammation, fibrosis, and …

Published: May 23, 2026, midnight
Antagonizing the corticotropin-releasing hormone receptor 1 with an orally bioavailable drug reduces endometriosis pain and associated adhesions†.

Estrogen stimulates corticotropin-releasing hormone (CRH) expression in endometrial tissue, and CRH signaling contributes to inflammation and pain, suggesting a mechanistic role in endometriosis pathophysiology. We previously identified elevated CRH receptor-1 …

Published: May 22, 2026, midnight
Targeting TLR4 Attenuates Endometriosis Progression by Suppressing NF-κB/NLRP3 Inflammasome Activation and Angiogenesis.

Endometriosis is a chronic inflammatory disorder affecting approximately 10% of reproductive-age women, yet non-hormonal therapeutic options remain limited. This study investigates the role of the TLR4/NF-κB/NLRP3 inflammasome axis in endometriosis …

Published: May 6, 2026, midnight
Terazosin as a Non-Hormonal Treatment for Endometriosis.

Endometriosis is a chronic, estrogen-dependent inflammatory disease including aberrant local steroidogenesis, inflammation, angiogenesis, oxidative stress, and prostaglandin-mediated pain. Given the elevated adrenergic receptor expression in endometriotic lesions and the potential …

Published: May 2, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!